Principal Investigator
Matthew Schlumbrecht
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20221334
Clinical Trial Summary
A Phase 1b/2 Multicohort Umbrella Study To Evaluate The Safety And Efficacy Of Novel Treatments And/Or Combinations Of Treatments In Participants With Ovarian Cancer (Opal)
Cohort C: Open-Label Phase 2, Randomized, Controlled Multicenter Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy As Neoadjuvant Treatment In Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Gynecologic Cancer
Contact Information
Phone Number
+1 (305) 2434624